Drug efflux by Breast Cancer Resistance Protein (BCRP) is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924

BACKGROUND: Preclinical investigations have identified insulin-like growth factor (IGF) signaling as a key mechanism for cancer growth and resistance to clinically useful therapies in multiple tumor types, including breast cancer. Thus, agents targeting and blocking IGF signaling have promise in the...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Hou, Xiaonan, Huang, Fei, Carboni, Joan M., Flatten, Karen, Asmann, Yan W., Eyck, Cynthia Ten, Nakanishi, Takeo, Tibodeau, Jennifer D., Ross, Douglas D., Gottardis, Marco M., Erlichman, Charles, Kaufmann, Scott H., Haluska, Paul
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2011
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3057506/
https://ncbi.nlm.nih.gov/pubmed/21220496
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-10-0438
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak